\Multi-Center Phase I Study of Avutometinib (VS-6766), a RAF/MEK Clamp in Combination With Defactinib, a FAK Inhibitor, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway or NF2 Alterations
This study is testing a new medication called avutometinib, combined with another drug called defactinib, to see if it is safe for children and young adults with tough-to-treat solid tumors. Researchers want to find the best dose that shrinks tumors while keeping side effects as mild as possible.
This trial is for patients aged 3 to 30 years old who have certain types of childhood tumors with specific genetic changes. Participants also need to meet general health and physical ability requirements to join safely.
Participants will receive the study medications and be closely monitored by the medical team to check for safety and effectiveness. Your doctors will carefully track how your body responds to the treatment and watch for any side effects.
The study takes place at medical centers in Atlanta, Georgia, and New York, New York. Currently, the study is active but not actively looking for new participants.
- 1Tests a combination of new anti-cancer drugs for children and young adults.
- 2Aims to find the safest and most effective dose for hard-to-treat tumors.
- 3Currently active at specific locations in the United States, though not currently accepting new patients.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.